Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background & Aims</h3><p>Our previous genomic whole-exome sequencing (WES) data identified the key ErbB pathway mutations that play an essential role in regulating the malignancy of gallbladder cancer (GBC). Here, we tested the hypothesis that individual cellular components of the tumor microenvironment (TME) in GBC function differentially to participate in ErbB pathway mutation-dependent tumor progression.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We engaged single-cell RNA sequencing to reveal transcriptomic heterogeneity and intercellular crosstalk from 13 human GBC and adjacent normal tissues. In addition, we performed WES analysis to reveal the genomic variations related to tumor malignancy. A variety of bulk RNA sequencing, immunohistochemical staining, immunofluorescence staining and functional experiments were employed to study the difference between ErbB pathway mutation and non-mutation tissues.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>We identified sixteen cell types from a total of 114,927 cells, in which epithelial cells, M2 macrophages, and Treg were predominant in ErbB pathway mutation tumors. Furthermore, epithelial cell subtype 1, 2 and 3 were mainly found in the adenocarcinoma and subtype 4 was present in adenosquamous carcinoma. The ErbB pathway mutation tumors harbored larger populations of epithelial cell subtype 1 and 2, and expressed higher levels of secreted midkine (MDK) than non-ErbB pathway mutation tumors. Increased MDK resulted in interaction with its receptor LRP1 expressed by tumor infiltrating macrophages and promoted immuno-suppressive macrophage differentiation. Moreover, the crosstalk between macrophage-secreted CXCL10 and its receptor CXCR3 on Tregs was induced in GBC with ErbB pathway mutations. Elevated MDK was correlated with poor overall survival of GBC patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>This study has provided valuable insights into transcriptomic heterogeneity and the global cellular network in the TME, which coordinately functions to promote the progression of GBC with ErbB pathway mutations; thus unveiling novel cellular and molecular targets for cancer therapy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Lay summary</h3><p>We employed single-cell RNA sequencing and functional assays to reveal transcriptomic heterogeneity and intercellular crosstalk in GBC patients. GBC cancers were characterized with heterogenic cellular ecosystem in which the ErbB pathway mutations were associated with anti-cancer immunity and cancer development. Increased MDK from cancer cells of ErbB pathway mutation tumors resulted in interaction with its receptor LRP1 expressed by tumor infiltrating macrophages and promoted immuno-suppressive macrophage differentiation. In addition, the crosstalk between macrophage-secreted CXCL10 and its receptor CXCR3 on Tregs was induced in GBC with ErbB pathway mutations, which contributes to GBC progression.</p>

ERBB2 S310F Mutation Independently Activates PI3K/AKT and MAPK Pathways Through Homodimers to Contribute Gallbladder Carcinoma Growth

Genomic ERBB2 / ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.

The E545K Mutation of PIK3CA Promotes Gallbladder Carcinoma Progression Through Enhanced Binding to EGFR.

Whole-exome and Targeted Gene Sequencing of Gallbladder Carcinoma Identifies Recurrent Mutations in the ErbB Pathway

Oncogenic ERBB2 Aberrations and KRAS Mutations Cooperate to Promote Pancreatic Ductal Adenocarcinoma Progression.

ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer

Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer

Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine

PP4R1 promotes glycolysis and gallbladder cancer progression through facilitating ERK1/2 mediated PKM2 nuclear translocation

KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer

ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer

ERBB2 Mutation: A Promising Target in Non-Squamous Cervical Cancer

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2

A Novel Pi3k/Akt Signaling Axis Mediates Nectin-4-Induced Gallbladder Cancer Cell Proliferation, Metastasis and Tumor Growth

Identification of MAP Kinase Pathways As Therapeutic Targets in Gallbladder Carcinoma Using Targeted Parallel Sequencing.

PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway

Oncogenic Extracellular Domain Mutations Of Erbb2 In Cancer

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers

ERBB3 Mutations in Advanced Gastric Signet-Ring Cell Carcinoma (SRCC) and the Implications for Targeted Therapy

Knockdown of IGF2BP3 inhibits the tumorigenesis of gallbladder cancer and modifies tumor microenvironment

Genomic landscape of ERBB2/3 alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype.